InvestorsHub Logo
Followers 30
Posts 4349
Boards Moderated 0
Alias Born 03/20/2011

Re: None

Wednesday, 02/08/2023 5:56:54 PM

Wednesday, February 08, 2023 5:56:54 PM

Post# of 162
https://markets.businessinsider.com/news/stocks/analysts-offer-insights-on-healthcare-companies-neurocrine-nbix-and-immatics-imtx-1032070272

Immatics (IMTX)

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Immatics today. The company’s shares closed last Friday at $8.34.

According to TipRanks.com, Nakae is a 3-star analyst with an average return of 3.0% and a 40.3% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Better Therapeutics, Inc., and Emergent Biosolutions.

Currently, the analyst consensus on Immatics is a Moderate Buy with an average price target of $22.50.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMTX News